SRI-35241

Overview

SRI-35241 is a thrombospondin TSP-1 inhibitor with a pIC 50 of 8.12 nM against human targets. SRI-35241 inhibits the binding of TSP-1 to latent transforming growth factor-β-associated peptide ( LAP ) and blocks the activation of TGF-β . SRI-35241 shows a certain time-dependent property, with a plasma half-life of 1.8 h after intravenous administration. SRI-35241 can be used for the research of multiple myeloma and fibrotic diseases.

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Disease Areas > Multiple Myeloma | Products > Signaling Pathways > TGF-beta/Smad | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Research Areas > Cancer | Products > Signaling Pathways > TGF-β Receptor

Product Information

• Catalog No.: HY-182612
• CAS No.: 2307429-54-3
• Molecular Formula: C11H22N4O3
• Molecular Weight: 258.32
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source